Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Expositio...
November 07 2019 - 8:00AM
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that
Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a
poster presentation at the upcoming 61st American Society of
Hematology (ASH) Annual Meeting and Exposition being held in
Orlando, FL from December 7-10, 2019.
Trials in Progress Poster
Details:
Presentation
Title: Hyper-Sialylated IgG M254, an Innovative
Therapeutic Candidate, Evaluated in Healthy Volunteers and in
Patients with Immune Thrombocytopenia Purpura: Safety,
Tolerability, Pharmacokinetics, and Pharmacodynamics
Session
Name: 311. Disorders of Platelet Number or Function:
Poster I
Presenter: Santiago Arroyo, M.D., Ph.D.
Date:
Saturday, December 7, 2019
Presentation
Time: 5:30 pm - 7:30 pm ET
Location: Orange County Convention Center, Hall
B
A copy of the presentation materials can be
accessed on the Publications section of the Momenta website once
the presentation concludes.
About M254, Hypersialylated Immunoglobulin
G
M254 is a hypersialylated human immunoglobulin G
(hsIgG), engineered with significantly enhanced tetra-sialylation.
In preclinical studies of ITP and other inflammatory diseases, M254
has shown an increase in potency of up to ten times that of
conventional IVIg. IVIg has been used for more than 30 years for
the treatment of a variety of acute and chronic autoimmune and
systemic inflammatory diseases. We believe this product has the
potential to be developed as a high-potency alternative to
IVIg.
About Momenta
Momenta Pharmaceuticals is a biotechnology company
with a validated innovative scientific platform focused on
discovering and developing novel therapeutics to treat rare,
immune-mediated diseases and advancing its late stage biosimilar
portfolio. The company is headquartered in Cambridge, MA.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does not
form a part of this press release.
The Company’s logo, trademarks, and service marks
are the property of Momenta Pharmaceuticals, Inc. All other trade
names, trademarks, or service marks are property of their
respective owners.
Forward-Looking Statements
Statements in this press release regarding
management's future expectations, beliefs, intentions, goals,
strategies, plans or prospects, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including but not limited to statements about the timing
of our regulatory filings for clinical development and marketing
approval; the timing of regulatory approval and launch of our
product candidates; development design, timelines and strategies;
the Company’s ability to meet its development and strategic goals;
hypotheses regarding certain actions and effects of our product
candidates; market potential and revenue of our products and
product candidates, design, timing and goals of clinical trials and
the availability, timing and announcement of data and results; the
use, efficacy, safety, potency, tolerability, convenience, dosing
and commercial potential and reception of our product candidates.
Forward-looking statements may be identified by words such as
"believe," "continue," “plan to”, "potential," "will," and other
similar words or expressions, or the negative of these words or
similar words or expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other important
factors, including those referred to under the section "Risk
Factors" in the Company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2019 filed with the Securities and
Exchange Commission, as well as other documents that may be filed
by the Company from time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and factors,
the Company's actual results may differ materially from any future
results, performance or achievements discussed in or implied by the
forward-looking statements contained herein. The Company is
providing the information in this press release as of this date and
assumes no obligations to update the information included in this
press release or revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
INVESTOR CONTACT:Patty EisenhaurMomenta
Pharmaceuticals1-617-395-5189IR@momentapharma.com
MEDIA CONTACT:Karen
SharmaMacDougall1-781-235-3060momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Sep 2023 to Sep 2024